Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Total Liabilities: 2022-2025

Historic Total Liabilities for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to $72.2 million.

  • Entrada Therapeutics' Total Liabilities fell 45.38% to $72.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.2 million, marking a year-over-year decrease of 45.38%. This contributed to the annual value of $97.6 million for FY2024, which is 56.95% down from last year.
  • Per Entrada Therapeutics' latest filing, its Total Liabilities stood at $72.2 million for Q3 2025, which was up 4.19% from $69.3 million recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Total Liabilities registered a high of $287.1 million during Q2 2023, and its lowest value of $39.3 million during Q1 2022.
  • Moreover, its 3-year median value for Total Liabilities was $152.0 million (2024), whereas its average is $166.6 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first surged by 619.88% in 2023, then tumbled by 71.34% in 2025.
  • Entrada Therapeutics' Total Liabilities (Quarterly) stood at $39.5 million in 2022, then soared by 474.23% to $226.8 million in 2023, then tumbled by 56.95% to $97.6 million in 2024, then tumbled by 45.38% to $72.2 million in 2025.
  • Its Total Liabilities stands at $72.2 million for Q3 2025, versus $69.3 million for Q2 2025 and $69.2 million for Q1 2025.